No Data
Qiagen N.V.'s (NYSE:QGEN) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
QIAGEN, Lilly to Develop Alzheimer's Risk Detection Test
QIAGEN Enters Collaboration With Eli Lilly To Support Development Of QIAstat-Dx In-vitro Diagnostic To Detect APOE Genotypes Which Can Play Role In Diagnosis Of Alzheimer's Disease; No Terms Disclosed
QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds
QIAGEN Expands Master Collaboration Agreement With AstraZeneca's Future Therapies To Develop And Validate A Genotyping Assay Using Co's Syndromic Testing Platform QIAstat-Dx
Berenberg Lifts Price Target on Qiagen to EUR54.90 From EUR54.20, Keeps Buy Rating
There's Reason For Concern Over Qiagen N.V.'s (NYSE:QGEN) Price
No Data
